Skip to main content

Table 1 Association of ALDH1 expression with clinical and pathologic factors in breast cancer tissues ( χ 2 test)

From: Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse

  n ALDH1A1 expression P value
+ ++ +++
Age (years) 147 52.2 ± 11.9 51.6 ± 13.0 53.2 ± 13.0 48.5 ± 12.7 0.682
Tumor size (cm) 147 3.9 ± 0.6 2.6 ± 0.2 2.9 ± 0.6 3.9 ± 0.5 0.103
Lymph node involvement 115 45 (39.1%) 45 (39.1%) 9 (4.0%) 16 (13.9%) 0.389
TNM stages       
I 14 4 (28.6%) 8 (57.1%) 1 (7.1%) 1 (7.1%) 0.177
II 56 19 (33.9%) 25 (44.6%) 6 (10.7%) 6 (10.7%)  
III 76 31 (40.8%) 29 (38.2%) 5 (6.6%) 11 (14.5%)  
IV 1 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%)  
NOTCH1 expression      
9 7 (77.8%) 2 (22.2%) 0 (0.0%) 0 (0.0%) 0.044
+ 26 7 (26.9%) 17 (65.4%) 2 (7.7%) 0 (0.0%)  
++ 24 10 (41.7%) 8 (33.3%) 1 (4.2%) 5 (20.8%)  
+++ 88 30 (34.1%) 36 (40.9%) 8 (9.1%) 14 (15.9%)  
Ki67 expression       
79 38 (48.1%) 35 (44.3%) 6 (7.6%) 0 (0.0%) 0.001
+ 68 16 (23.5%) 28 (41.2%) 5 (7.4%) 19 (27.9%)  
P53 expression       
100 35 (35.0%) 45 (45.0%) 8 (8.0%) 12 (12.0%) 0.823
+ 47 19 (40.4%) 18 (38.3%) 3 (6.4%) 7 (14.9%)  
ER expression       
90 34 (37.8%) 35 (38.9%) 6 (6.7%) 15 (16.7%) 0.303
+ 57 20 (35.1%) 28 (47.4%) 5 (8.8%) 4 (7.0%)  
PR expression       
83 27 (32.5%) 38 (45.8%) 5 (6.0%) 13 (15.7%) 0.400
+ 64 27 (42.2%) 25 (39.1%) 6 (9.4%) 6 (9.4%)  
HER2 expression      
77 32 (41.6%) 32 (41.6%) 4 (5.2%) 9 (11.7%) 0.492
+ 70 22 (31.4%) 31 (44.3%) 7 (10.0%) 10 (14.3%)  
Triple negativity features*     
108 40 (37.0%) 44 (40.7%) 10 (9.3%) 14 (13.0%) 0.541
+ 39 14 (35.9%) 19 (48.7%) 1 (2.6%) 5 (12.8%)  
Local recurrence     
Present 40 8 (20.0%) 20 (50.0%) 6 (15.0%) 6 (15.0%) 0.027
Absent 107 46 (43.0%) 43(40.2%) 5 (4.7%) 13 (12.1%)  
Distant metastasis     
Present 51 21 (41.1%) 20 (39.2%) 3 (5.9%) 7 (13.7%) 0.809
Absent 96 33 (34.3%) 43 (44.8%) 8 (8.3%) 12 (12.5%)  
  1. ALDH aldehyde dehydrogenase, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
  2. * Immunohistochemically negative for ER, PR, and HER2.